<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25180" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Minocycline</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nazarian</surname>
            <given-names>Simon</given-names>
          </name>
          <aff>Saint James School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akhondi</surname>
            <given-names>Hossein</given-names>
          </name>
          <aff>University of Nevada</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Simon Nazarian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hossein Akhondi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>11</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25180.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Minocycline belongs to the tetracycline class of antibiotics and is used to manage and treat both infectious and non-infectious conditions.&#x000a0;In addition to its effectiveness against both gram-positive and gram-negative bacteria, minocycline also exhibits anti-inflammatory, antioxidant, anti-apoptotic, and immunomodulatory properties.&#x000a0;Furthermore, this medication is recognized as the most effective tetracycline derivative in terms of its ability to provide neuroprotective effects.&#x000a0;This activity describes minocycline's mechanism of action, indications, and contraindications as a valuable agent in treating and managing bacterial infections and conditions such as acne, neurodegenerative diseases, periodontitis, and dermatitis. This activity also&#x000a0;highlights&#x000a0;the adverse event profile, dosing, pharmacodynamics, pharmacokinetics, monitoring, and other relevant interactions of&#x000a0;minocycline.&#x000a0;These are crucial considerations for healthcare professionals engaged in treating patients with the conditions mentioned above.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the diverse indications of minocycline encompassing bacterial infections, acne, neurodegenerative disorders, periodontitis, and dermatitis.</p></list-item><list-item><p>Implement appropriate dosing strategies and treatment regimens for patients receiving minocycline therapy while considering their age, weight, and renal function factors.</p></list-item><list-item><p>Apply evidence-based guidelines and clinical protocols to optimize minocycline therapy for various conditions in specific patient populations.</p></list-item><list-item><p>Communicate effectively with patients about the benefits, potential risks, and expectations of minocycline therapy, ensuring informed decision-making.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25180&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25180">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25180.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Minocycline is a semi-synthetic second-generation tetracycline and a broad-spectrum antibiotic. This drug was synthesized in 1967 for managing and treating numerous infectious and non-infectious diseases. Furthermore, minocycline's anti-infectious potency aligns closely with that of other tetracyclines.&#x000a0;In addition to its effectiveness against both gram-positive and gram-negative bacteria, minocycline exhibits anti-inflammatory, antioxidant, anti-apoptotic, and immunomodulatory properties. This medication is also recognized as the most effective tetracycline derivative in terms of its ability to provide neuroprotective effects.&#x000a0;This distinction arises from its high lipophilicity, enabling it to traverse the blood-brain barrier with exceptional efficacy.<xref ref-type="bibr" rid="article-25180.r1">[1]</xref></p>
        <p>In general, it has been observed that an individual susceptible to tetracycline may also be susceptible to minocycline.<xref ref-type="bibr" rid="article-25180.r2">[2]</xref> Minocycline's spectrum of coverage includes <italic toggle="yes">Borrelia recurrentis</italic>, <italic toggle="yes">Mycobacterium marinum,</italic>
<italic toggle="yes">Mycoplasma pneumoniae,</italic>
<italic toggle="yes">Staphylococcus aureus,</italic> including methicillin-resistant <italic toggle="yes">Staphylococcus aureus,</italic>
<italic toggle="yes">Vibrio vulnificus,</italic> and susceptible strains of vancomycin-resistant <italic toggle="yes">Enterococcus</italic>. Minocycline is also used in&#x000a0;the treatment of rickettsial infections, chlamydial infections, syphilis, pelvic inflammatory disease, acne, nocardiosis, brucellosis, ehrlichiosis, amebiasis, actinomycosis, anaplasmosis, leptospirosis, melioidosis, tularemia, traveler's diarrhea, early-stage Lyme disease, Legionnaire disease, and Whipple disease.<xref ref-type="bibr" rid="article-25180.r3">[3]</xref>&#x000a0;</p>
        <p>According to&#x000a0;the&#x000a0;Infectious Diseases Society of America (IDSA) 2022 guidelines, minocycline has been recognized as an effective medication against carbapenem-resistant <italic toggle="yes">Acinetobacter baumannii</italic> and <italic toggle="yes">Stenotrophomonas maltophilia</italic>.<xref ref-type="bibr" rid="article-25180.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Various&#x000a0;off-label&#x000a0;uses of minocycline include&#x000a0;rosacea, bullous dermatoses, neutrophilic diseases, pyoderma gangrenosum, sarcoidosis, aortic aneurysms, cancer metastasis, periodontitis, and autoimmune disorders such&#x000a0;as&#x000a0;scleroderma and rheumatoid arthritis, according to the American College of Rheumatology guidelines.<xref ref-type="bibr" rid="article-25180.r5">[5]</xref><xref ref-type="bibr" rid="article-25180.r6">[6]</xref><xref ref-type="bibr" rid="article-25180.r7">[7]</xref></p>
      </sec>
      <sec id="article-25180.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Protein synthesis occurs through ribosomes in both eukaryotic and prokaryotic cells, facilitating the transformation of messenger RNA (mRNA) codes into functional proteins. The ribosomes in&#x000a0;prokaryotic cells&#x000a0;consist of the 30S and 50S subunits, whereas in eukaryotic cells, they consist of&#x000a0;the 40S and 60S subunits. In prokaryotic and eukaryotic organisms, the&#x000a0;2 ribosomal subunits&#x000a0;converge at the mRNA template, facilitating the transfer RNA (tRNA) to transport an amino acid and form&#x000a0;cellular proteins by elongating amino acid chains.</p>
        <p>Tetracyclines, such as minocycline, bind to the 30S ribosomal subunit, preventing charged tRNA from delivering amino acids to elongate the protein chain and develop a cellular protein. This disruption results in a bacteriostatic impact on the prokaryotic cell, causing the organism to lose its capability to grow or replicate.<xref ref-type="bibr" rid="article-25180.r8">[8]</xref>&#x000a0;</p>
        <p>Tetracyclines are lipid-soluble compounds capable of transportation across hydrophobic barriers, including biological membranes. Their lipophilic nature enables rapid absorption and distribution throughout the organism. Among tetracyclines, minocycline exhibits greater lipophilicity than&#x000a0;doxycycline, resulting in elevated concentrations in the central nervous system (CNS) and the skin.<xref ref-type="bibr" rid="article-25180.r9">[9]</xref></p>
        <p>Minocycline is accessible for administration in both oral and parenteral formulations. The intravenous (IV) route has been&#x000a0;used to treat&#x000a0;conditions such as pneumonia, bloodstream infections, and skin and skin structure infections.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Absorption:&#x000a0;Oral forms are absorbed within the stomach and proximal small intestine. Absorption rates depend on the presence of food, especially items containing divalent cations such as calcium. These cations chelate with minocycline and other tetracyclines, rendering them non-absorbable.<xref ref-type="bibr" rid="article-25180.r10">[10]</xref></p>
        <p>Distribution: Due&#x000a0;to its enhanced lipophilicity compared to other tetracyclines, such as doxycycline, minocycline attains elevated concentrations in the CNS and the skin. Minocycline achieves a greater concentration in saliva compared to tetracycline and doxycycline,&#x000a0;accounting for the drug's effectiveness in addressing the meningococcal carrier stage. The volume of distribution ranges from 0.14 to 0.7 L/kg.<xref ref-type="bibr" rid="article-25180.r9">[9]</xref></p>
        <p>Metabolism: The primary metabolic pathways for minocycline involve hydroxylation and <italic toggle="yes">N</italic>-demethylation, primarily mediated by the enzyme CYP3A4.<xref ref-type="bibr" rid="article-25180.r11">[11]</xref></p>
        <p>Elimination: The serum half-life of minocycline varies between 11 and 24 hours, with an average of 17 hours. Approximately 5% to 12% of minocycline is eliminated unchanged in the urine.<xref ref-type="bibr" rid="article-25180.r12">[12]</xref></p>
      </sec>
      <sec id="article-25180.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Minocycline is available in various forms, including oral tablets, capsules, IV injections, and topical foam. The available dosage forms and strengths of minocycline&#x000a0;are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Oral capsules: These&#x000a0;are available in strengths of 50 mg, 75 mg, and 100 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Extended-release oral capsules (24-hour): These&#x000a0;are offered in strengths of 45 mg, 90 mg, and 135 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Oral tablets: These are provided in strengths of 50 mg, 75 mg, and 100 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Extended-release oral tablets (24-hour): These are available in strengths of 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg, and 135 mg.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>IV solution: IV solution, when reconstituted, provides a concentration of 100 mg per vial.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Topical foam: This is available in 2 variations, including a 1.5% aerosol foam and a 4% aerosol foam.</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Consuming adequate amounts of liquid when ingesting oral capsules or tablets from the tetracycline drug class is&#x000a0;recommended to mitigate the risk of esophageal irritation and ulceration.&#x000a0;The standard recommended oral dosage regimen for minocycline capsules or tablets typically involves an initial dose of 200 mg, followed by 100 mg of minocycline every 12 hours. The typical oral dosage for pediatric patients aged 8 or older is 4 mg/kg of minocycline initially, followed by 2 mg/kg of minocycline every 12 hours.</p>
        <p>The&#x000a0;below points&#x000a0;outline the diverse applications of minocycline in medical treatment, emphasizing distinct treatment durations and dosage recommendations for optimal outcomes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Acne vulgaris finds an effective remedy in minocycline, as underscored by the American Academy of Dermatology guidelines.<xref ref-type="bibr" rid="article-25180.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Uncomplicated gonococcal infections, excluding urethritis or anorectal infections in men, undergo a 4-day treatment regimen with minocycline, complemented by post-therapy cultures conducted within 2 to 3 days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Uncomplicated gonococcal urethritis in men necessitates a 5-day minocycline treatment course for effective resolution.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Syphilis management entails a treatment period of 10 to 15 days with minocycline, accompanied by meticulous follow-up and laboratory assessments.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For individuals with the meningococcal carrier state, the advised minocycline dosage is 100 mg every 12 hours for 5 days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In treating <italic toggle="yes">M marinum</italic> infection, while optimal doses of the medication&#x000a0;remain unspecified, a successful approach has been observed with 100 mg of minocycline administered every 12 hours for 6 to 8 weeks, albeit in a limited patient cohort.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For adults dealing with uncomplicated endocervical, urethral, or rectal infections attributed to <italic toggle="yes">Chlamydia trachomatis</italic> or <italic toggle="yes">Ureaplasma urealyticum</italic>, an effective regimen involves an oral dosage of 100 mg of minocycline&#x000a0;administered every 12 hours for a minimum duration of 7 days.</p>
          </list-item>
        </list>
        <p>
<bold>Extended-release formulation dosage</bold>
</p>
        <p>The recommended oral dosage for the extended-release form of minocycline is 1 mg/kg, administered to patients once daily and sustained over 12 weeks.&#x000a0;Notably, administering higher doses of minocycline to patients has not demonstrated added advantages in addressing inflammatory acne lesions, potentially leading to an increased occurrence of acute vestibular adverse effects.<bold>&#x000a0;</bold></p>
        <p>
<bold>IV dosage</bold>
</p>
        <p>Minocycline IV therapy is recommended for patients who cannot tolerate the oral form of the treatment. However, oral therapy should be initiated at the earliest convenience.&#x000a0;Prolonged IV therapy might lead to thrombophlebitis; therefore, caution is advised against rapid administration to mitigate such risks.</p>
        <list list-type="bullet">
          <list-item>
            <p>The recommended initial IV dosage of minocycline for adults is 200 mg, followed by an additional 100 mg administered intravenously over 60 minutes every 12 hours.&#x000a0;Notably, the total dosage should not exceed 400 mg within a 24-hour time frame.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The standard initial dosing of minocycline for pediatric patients&#x000a0;is&#x000a0;4 mg/kg, followed by 2 mg/kg of the medication administered over a 60-minute duration every 12 hours.&#x000a0;Notably,&#x000a0;pediatric dosages should not exceed the recommended adult dosage recommendations.</p>
          </list-item>
        </list>
        <p>The lyophilized powder for injection necessitates reconstitution of minocycline&#x000a0;with 5 mL of sterile water for injection USP, followed by immediate additional dilution in a solution of 100 mL to 1000 mL containing dextrose injection USP, sodium chloride injection USP, dextrose or sodium chloride injection USP, or 250 mL to 1000 mL of lactated Ringer injection USP. Minocycline should not be diluted with calcium solutions due to the risk of precipitate formation, particularly in neutral or alkaline solutions. After dilution into an IV bag, the injection can be stored at room temperature for a maximum of 4 hours or refrigerated at 36&#x000a0;&#x000b0;F to 46 &#x000b0;F (or 2 &#x000b0;C to 8 &#x000b0;C) for up to 24 hours. Any remaining unused portions of the medication must be discarded after the designated time frame.</p>
        <p>
<bold>Topical foam&#x000a0;</bold>
</p>
        <p>The minocycline topical foam should be gently applied as a thin layer over the affected facial area&#x000a0;to treat inflammatory lesions of rosacea in adults.&#x000a0;This application should occur around the same time each day, with a recommended interval of at least 1 hour before bedtime. In addition, patients are advised to refrain from showering, bathing, or swimming for at least 1 hour after applying the medication.<xref ref-type="bibr" rid="article-25180.r14">[14]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p>Hepatic impairment: No dosage adjustment is necessary for patients with impaired hepatic function. However, it is essential to exercise caution, as cases of hepatotoxicity have been reported with minocycline use.<xref ref-type="bibr" rid="article-25180.r15">[15]</xref></p>
        <p>Renal impairment: For patients with compromised renal function, it is advisable to lower the total daily minocycline dosage by reducing the prescribed individual patient doses or extending the time intervals between them.</p>
        <p>Pregnancy considerations:&#x000a0;Minocycline is classified by the U.S. Food and Drug Administration (FDA) as a pregnancy Category D medicine. Due to their potential for permanent discoloration of teeth and impairment of long bone growth in the fetus, pregnant women should avoid tetracyclines.<xref ref-type="bibr" rid="article-25180.r16">[16]</xref> Notably, the use of topical minocycline products is not contraindicated during pregnancy.</p>
        <p>Breastfeeding considerations: Existing literature suggests that short-term usage of minocycline by nursing mothers is deemed acceptable. This is attributed to the low levels of minocycline excreted in breast milk and the fact that the calcium present in breast milk inhibits the infant's additional absorption of the drug. Caution should be exercised against prolonged or repeated courses of minocycline during breastfeeding. The breastfed infant must be vigilantly observed for any signs of rash, diarrhea, or candidiasis, which includes symptoms such as thrush or diaper rash. In addition, nursing mothers should be aware that minocycline usage has been associated with instances of black discoloration in breast milk.<xref ref-type="bibr" rid="article-25180.r17">[17]</xref></p>
        <p>Pediatric patients: According to IDSA guidelines, minocycline is recommended for treating infections caused by <italic toggle="yes">S aureus</italic> in patients aged 8 and older.<xref ref-type="bibr" rid="article-25180.r18">[18]</xref></p>
        <p>Older patients: Due to the potential for impaired hepatic and renal function, it is prudent to commence with a lower starting dose of minocycline for older populations. In addition, caution must be exercised when treating patients concurrently taking multiple medications with minocycline due to the potential for drug interactions.<xref ref-type="bibr" rid="article-25180.r19">[19]</xref></p>
      </sec>
      <sec id="article-25180.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Frequently encountered adverse effects of minocycline encompass gastrointestinal distress and heightened photosensitivity. Instances of skin hyperpigmentation and nail discoloration are also feasible. Although children are more prone to teeth staining and&#x000a0;bone growth inhibition, reports&#x000a0;indicate that these effects may occur even in adults.&#x000a0;The prevalence of tooth discoloration attributed to minocycline use is estimated to be within the range of 3% to 6%.<xref ref-type="bibr" rid="article-25180.r20">[20]</xref><xref ref-type="bibr" rid="article-25180.r21">[21]</xref> Notably, hepatotoxicity is a potential concern associated with minocycline usage, and therefore a risk of exacerbating preexisting renal failure should also be considered.<xref ref-type="bibr" rid="article-25180.r15">[15]</xref></p>
        <p>Pill esophagitis, characterized by symptoms such as chest pain, odynophagia, and dysphagia, has been documented as an adverse effect of minocycline. This effect can be mitigated by consuming oral minocycline formulations with sufficient water and maintaining an upright posture after ingesting the medication.<xref ref-type="bibr" rid="article-25180.r22">[22]</xref>&#x000a0;Although&#x000a0;adverse effects caused by minocycline treatment are infrequent, the elevated concentrations of the drug in the CNS compared to other tetracyclines contribute to the dose-limiting vestibular adverse effects such as nausea, vomiting, vertigo, dizziness, or hearing loss.<xref ref-type="bibr" rid="article-25180.r23">[23]</xref><xref ref-type="bibr" rid="article-25180.r24">[24]</xref> Studies have additionally established a connection between the utilization of tetracyclines and the occurrence of idiopathic intracranial hypertension, also known as pseudotumor cerebri.</p>
        <p>A&#x000a0;reported association exists between minocycline use and systemic lupus erythematosus (SLE), with a reported risk of 8.8 cases per 100,000 person-years.<xref ref-type="bibr" rid="article-25180.r25">[25]</xref>&#x000a0;In addition, tetracycline usage has been associated with correlations to drug-induced pancreatitis.<xref ref-type="bibr" rid="article-25180.r26">[26]</xref> Similar to other antibiotics, minocycline increases the&#x000a0;risk of <italic toggle="yes">Clostridium difficile</italic> infection development. However, the risk is comparatively lower than that associated with other antibiotics.<xref ref-type="bibr" rid="article-25180.r27">[27]</xref>&#x000a0;Minocycline use is associated with dermatological reactions, including drug rash with eosinophilia and systemic symptoms (DRESS), leading to fatal outcomes. As a result, immediate discontinuation of minocycline is imperative if symptoms of DRESS are identified.</p>
        <p>
<bold>Drug-Drug and Drug-Food Interactions</bold>
</p>
        <p>Understanding the potential interactions between minocycline and other drugs or food is crucial for optimizing treatment efficacy and patient safety.</p>
        <p>Minerals: Supplements or food containing minerals, such as calcium, magnesium, folate, or iron, can lead to a reduction in the blood concentration of minocycline. Hence, whenever feasible, patients are advised to refrain from taking both the medication and minerals simultaneously. When coadministration cannot be circumvented, it is recommended to administer these substances at least 2 hours&#x000a0;before or 4 hours after the oral administration of minocycline.<xref ref-type="bibr" rid="article-25180.r28">[28]</xref> This principle also extends to calcium-rich foods; therefore, individuals should avoid consuming dairy products, such as milk, yogurt, cheese, or ice cream, along with their medication. However, patients do not have to eliminate dairy from their diet, but they should ensure that these foods are consumed at least 1 hour before or 2 hours after taking minocycline.</p>
        <p>Antacids: Antacids, including aluminum hydroxide, calcium carbonate, and magnesium hydroxide, can reduce the absorption of tetracyclines by creating insoluble chelate complexes with these medications.<xref ref-type="bibr" rid="article-25180.r29">[29]</xref></p>
        <p>Isotretinoin: The simultaneous use of isotretinoin and minocycline should be avoided during therapy due to the elevated risk of pseudotumor cerebri.<xref ref-type="bibr" rid="article-25180.r30">[30]</xref></p>
        <p>Ergotism: Combining tetracycline derivatives with ergot alkaloids, such as ergotamine and dihydroergotamine, can result in a heightened risk of ergotism and acute limb ischemia. Consequently, it is advised to steer clear of this combination.<xref ref-type="bibr" rid="article-25180.r31">[31]</xref></p>
        <p>Drug-laboratory test interactions: The administration of minocycline therapy can generate false-positive urinary catecholamine levels, even in the absence of pheochromocytoma.<xref ref-type="bibr" rid="article-25180.r32">[32]</xref></p>
      </sec>
      <sec id="article-25180.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As all tetracyclines, including minocycline, can cross the placental barrier, they are&#x000a0;contraindicated during pregnancy. The additional risk associated with hepatotoxicity in pregnant individuals is also a factor that underscores the importance of avoiding the use of this drug in such cases.<xref ref-type="bibr" rid="article-25180.r33">[33]</xref><xref ref-type="bibr" rid="article-25180.r34">[34]</xref>&#x000a0;Individuals aged 8 or younger should avoid using minocycline to prevent permanent teeth discoloration for teeth that have not yet erupted. Therefore, pediatric patients between the ages of 13&#x000a0;and 19 should avoid minocycline use until all of their tooth crowns have developed.<xref ref-type="bibr" rid="article-25180.r35">[35]</xref> Clinicians should be aware that the administration of expired tetracyclines can lead to the development of Fanconi syndrome.<xref ref-type="bibr" rid="article-25180.r36">[36]</xref></p>
        <p>Although avoiding most tetracycline group medications in patients with chronic renal failure is generally recommended, it is essential to note that renal function does not influence minocycline elimination.<xref ref-type="bibr" rid="article-25180.r37">[37]</xref>&#x000a0;Higher&#x000a0;doses of minocycline have been observed to elevate urea excretion in healthy individuals. However, in cases of kidney impairment, minocycline's catabolic effects can potentially exacerbate uremia. Hence, closely monitoring both minocycline therapeutic doses and renal function in patients with renal failure is essential to prevent the worsening of uremia.<xref ref-type="bibr" rid="article-25180.r38">[38]</xref></p>
      </sec>
      <sec id="article-25180.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>A&#x000a0;prolonged therapeutic dosage of minocycline up to 200 mg daily is considered safe and well tolerated. The majority of adverse effects, such as nausea and dizziness, typically manifest shortly after the administration of minocycline and tend to subside soon after discontinuing the medication.&#x000a0;Baseline measurements of blood urea nitrogen (BUN) and serum creatinine should be obtained for patients, and regular monitoring should be maintained thereafter. Clinicians advise that after 6 months of minocycline treatment, all patients should undergo an assessment every 3 months to detect potential adverse effects, including hepatotoxicity, pigmentation issues, and the onset or progression of&#x000a0;SLE.<xref ref-type="bibr" rid="article-25180.r7">[7]</xref>&#x000a0;</p>
        <p>After administering 200 mg of minocycline intravenously, peak serum concentrations are observed within a range of 3 to 8.75 mg/L.<xref ref-type="bibr" rid="article-25180.r10">[10]</xref> The half-life of minocycline can vary from 13 hours for a single oral dose of 200 mg to 21 hours for a single IV dose of 200 mg. Studies indicate that serum concentration levels of minocycline do not correlate with renal function, and approximately 20% to 35% of the dose is eliminated through feces. Consequently, neither renal impairment nor end-stage renal disease significantly impacts the serum concentration or half-life of minocycline.<xref ref-type="bibr" rid="article-25180.r39">[39]</xref></p>
        <p>Minocycline's anti-anabolic effect can potentially result in an elevation of BUN. Patients with normal renal function typically do not encounter adverse effects. However, in significantly impaired renal function cases, minocycline administration can lead to complications such as azotemia, hyperphosphatemia, and acidosis. Given these circumstances, conducting regular monitoring of BUN and creatinine levels is advisable.<xref ref-type="bibr" rid="article-25180.r40">[40]</xref></p>
        <p>Regularly monitoring the prothrombin time&#x02013;international normalized ratio (PT/INR) and making appropriate dosage adjustments for warfarin is recommended when coadministering with minocycline.<xref ref-type="bibr" rid="article-25180.r41">[41]</xref><xref ref-type="bibr" rid="article-25180.r42">[42]</xref></p>
      </sec>
      <sec id="article-25180.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Common adverse effects and autoimmune reactions necessitate discontinuing minocycline and transitioning to an alternative antibiotic outside the tetracycline class. Interprofessional healthcare team members should be aware that minocycline carries a significantly higher risk of developing SLE than other tetracyclines. Consequently, a heightened level of suspicion is essential, and if symptoms manifest, immediate discontinuation of the medication alongside appropriate supportive measures is strongly recommended.<xref ref-type="bibr" rid="article-25180.r25">[25]</xref><xref ref-type="bibr" rid="article-25180.r3">[3]</xref></p>
        <p>The adverse events that are more frequently observed in cases of minocycline overdose include dizziness, nausea, and vomiting. There is no specific antidote available for minocycline. In the case of minocycline overdosage, the appropriate precautionary steps include discontinuing the medication, addressing the patient's symptoms symptomatically, and implementing supportive measures.<xref ref-type="bibr" rid="article-25180.r15">[15]</xref></p>
        <p>Minocycline cannot be effectively removed substantially through hemodialysis or peritoneal dialysis. The underlying mechanism behind drug-induced hepatotoxicity associated with minocycline is immunological. Autoimmune hepatitis caused by minocycline can lead to fatal outcomes; therefore, discontinuing minocycline usage is recommended. Corticosteroids and immunosuppressive agents are used to treat minocycline-induced autoimmune hepatitis.<xref ref-type="bibr" rid="article-25180.r15">[15]</xref></p>
      </sec>
      <sec id="article-25180.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although minocycline utilization has diminished due to apprehensions about factors such as irreversible pigmentation, high cost, and teratogenic effects, it remains imperative for the interprofessional healthcare team to have a comprehensive understanding of the drug's indications and potential adverse effects when contemplating its use. The escalating prevalence of antibiotic resistance within the community could potentially lead to a resurgence in the utility and widespread prescription of this antibiotic. Dermatologists frequently prescribe minocycline for the treatment of acne. Seeking consultation from infectious disease specialists is critical to address cases involving carbapenem-resistant microorganisms.</p>
        <p>Using targeted drug-susceptibility therapy not only benefits individual patients but also contributes to the well-being of society as a whole.&#x000a0;Infectious disease specialists and pharmacists typically possess the most recent antibiogram data, making their expertise invaluable in this approach.&#x000a0;The entire interprofessional healthcare team must engage in collaborative efforts to ascertain the suitability of minocycline as the appropriate therapeutic agent. In addition, it is essential to ensure that the patient comprehends both the potential risks and benefits associated with the medication.&#x000a0;Clinicians and pharmacists should provide patients with comprehensive guidance concerning potential adverse effects and the importance of adhering to the prescribed regimen. In instances of pseudotumor cerebri, seeking consultation from both a neurologist and an ophthalmologist is essential.&#x000a0;In cases of minocycline-induced autoimmune hepatitis, seeking consultation from a gastroenterologist or hepatologist is imperative. Emergency medicine physicians, advanced practice practitioners, and nursing staff should swiftly stabilize patients in the event of an overdose.</p>
        <p>Effective collaboration within the interprofessional healthcare team is critical in enhancing patient outcomes by diminishing the occurrence of adverse drug reactions. This approach enhances the likelihood of patient compliance with medication regimens and contributes to a reduction in morbidity and mortality rates.<xref ref-type="bibr" rid="article-25180.r43">[43]</xref>&#x000a0;</p>
        <p>The interprofessional team approach involves a collective effort of physicians, specialists, advanced practice practitioners, nursing staff, and pharmacists, with a specific emphasis on infectious disease specialty pharmacists. This team collaborates cohesively, leveraging their respective expertise, fostering open communication, and participating in shared decision-making to optimize patient outcomes related to minocycline therapy and minimize preventable adverse drug reactions.</p>
      </sec>
      <sec id="article-25180.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25180&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25180">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25180/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25180">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25180.s11">
        <title>References</title>
        <ref id="article-25180.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagarakanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bishburg</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Is Minocycline an Antiviral Agent? A Review of Current Literature.</article-title>
            <source>Basic Clin Pharmacol Toxicol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>118</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-8</page-range>
            <pub-id pub-id-type="pmid">26177421</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunha</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Sibley</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Ristuccia</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Doxycycline.</article-title>
            <source>Ther Drug Monit</source>
            <year>1982</year>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-35</page-range>
            <pub-id pub-id-type="pmid">7048645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Shutter</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Akhondi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Tetracycline</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">31751095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America Guidance on the Treatment of AmpC &#x003b2;-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Jul</month>
            <day>06</day>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>2089</fpage>
            <page-range>2089-2114</page-range>
            <pub-id pub-id-type="pmid">34864936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sapadin</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Fleischmajer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Tetracyclines: nonantibiotic properties and their clinical implications.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-65</page-range>
            <pub-id pub-id-type="pmid">16443056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saag</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Bridges</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McNaughton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shmerling</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Dell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Schousboe</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Drevlow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grober</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Tindall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>McAlindon</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-26</page-range>
            <pub-id pub-id-type="pmid">26545940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garrido-Mesa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zarzuelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000e1;lvez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Minocycline: far beyond an antibiotic.</article-title>
            <source>Br J Pharmacol</source>
            <year>2013</year>
            <month>May</month>
            <volume>169</volume>
            <issue>2</issue>
            <fpage>337</fpage>
            <page-range>337-52</page-range>
            <pub-id pub-id-type="pmid">23441623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chopra</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.</article-title>
            <source>Microbiol Mol Biol Rev</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-60 ; second page, table of contents</page-range>
            <pub-id pub-id-type="pmid">11381101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saivin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Houin</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of doxycycline and minocycline.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1988</year>
            <month>Dec</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>355</fpage>
            <page-range>355-66</page-range>
            <pub-id pub-id-type="pmid">3072140</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McConeghy</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Schreckenberger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Danziger</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>I.V. minocycline revisited for infections caused by multidrug-resistant organisms.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2016</year>
            <month>Mar</month>
            <day>01</day>
            <volume>73</volume>
            <issue>5</issue>
            <fpage>279</fpage>
            <page-range>279-85</page-range>
            <pub-id pub-id-type="pmid">26896499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wehring</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Elsobky</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Vyas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>DiPaula</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Buchanan</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.</article-title>
            <source>Psychiatr Q</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>89</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">28466366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhanel</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Homenuik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Noreddin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vercaigne</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Embil</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karlowsky</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hoban</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>The glycylcyclines: a comparative review with the tetracyclines.</article-title>
            <source>Drugs</source>
            <year>2004</year>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-88</page-range>
            <pub-id pub-id-type="pmid">14723559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zaenglein</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Pathy</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Schlosser</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Alikhan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Berson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bowe</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keri</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Stein Gold</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Tollefson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Dolan</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Sagan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bhushan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of acne vulgaris.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>May</month>
            <volume>74</volume>
            <issue>5</issue>
            <fpage>945</fpage>
            <page-range>945-73.e33</page-range>
            <pub-id pub-id-type="pmid">26897386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martins</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Marto</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Graber</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>A Review of Systemic Minocycline Side Effects and Topical Minocycline as a Safer Alternative for Treating Acne and Rosacea.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2021</year>
            <month>Jun</month>
            <day>22</day>
            <volume>10</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">34206485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Minocycline</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2019</year>
            <month>1</month>
            <day>23</day>
            <pub-id pub-id-type="pmid">31643289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goldbloom</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Haworth</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>LaRochelle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacLean</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Effects of tetracyclines on skeletal growth and dentition. A report by the Nutrition Committee of the Canadian Paediatric Society.</article-title>
            <source>Can Med Assoc J</source>
            <year>1968</year>
            <month>Nov</month>
            <day>02</day>
            <volume>99</volume>
            <issue>17</issue>
            <fpage>849</fpage>
            <page-range>849-54</page-range>
            <pub-id pub-id-type="pmid">4879536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <chapter-title>Minocycline</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevens</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bisno</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hirschmann</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Montoya</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>JC</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2014</year>
            <month>Jul</month>
            <day>15</day>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>e10</fpage>
            <page-range>e10-52</page-range>
            <pub-id pub-id-type="pmid">24973422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Vince</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isham</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meropol</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Polypharmacy in the elderly.</article-title>
            <source>J Res Pharm Pract</source>
            <year>2015</year>
            <season>Apr-Jun</season>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-8</page-range>
            <pub-id pub-id-type="pmid">25984546</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Sheridan</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Tetracycline and other tetracycline-derivative staining of the teeth and oral cavity.</article-title>
            <source>Int J Dermatol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>43</volume>
            <issue>10</issue>
            <fpage>709</fpage>
            <page-range>709-15</page-range>
            <pub-id pub-id-type="pmid">15485524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sparano</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Iatropoulos</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Hyperpigmentation of the skin associated with minocycline therapy.</article-title>
            <source>Arch Dermatol</source>
            <year>1985</year>
            <month>May</month>
            <volume>121</volume>
            <issue>5</issue>
            <fpage>618</fpage>
            <page-range>618-23</page-range>
            <pub-id pub-id-type="pmid">3158285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Koh</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Clinical and endoscopic characteristics of drug-induced esophagitis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>21</day>
            <volume>20</volume>
            <issue>31</issue>
            <fpage>10994</fpage>
            <page-range>10994-9</page-range>
            <pub-id pub-id-type="pmid">25152603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Safety of doxycycline and minocycline: a systematic review.</article-title>
            <source>Clin Ther</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>1329</fpage>
            <page-range>1329-42</page-range>
            <pub-id pub-id-type="pmid">16291409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Vestibular reactions associated with minocycline.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1975</year>
            <month>Oct</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>453</fpage>
            <page-range>453-6</page-range>
            <pub-id pub-id-type="pmid">1081373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garner</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Eady</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Popescu</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Minocycline for acne vulgaris: efficacy and safety.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Aug</month>
            <day>15</day>
            <volume>2012</volume>
            <issue>8</issue>
            <fpage>CD002086</fpage>
            <pub-id pub-id-type="pmid">22895927</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced acute pancreatitis: a review.</article-title>
            <source>Ochsner J</source>
            <year>2015</year>
            <season>Spring</season>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-51</page-range>
            <pub-id pub-id-type="pmid">25829880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tariq</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Orenstein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pardi</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Khanna</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>66</volume>
            <issue>4</issue>
            <fpage>514</fpage>
            <page-range>514-522</page-range>
            <pub-id pub-id-type="pmid">29401273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gr&#x000f6;ber</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Magnesium and Drugs.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Apr</month>
            <day>28</day>
            <volume>20</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">31035385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ogawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Echizen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clinically significant drug interactions with antacids: an update.</article-title>
            <source>Drugs</source>
            <year>2011</year>
            <month>Oct</month>
            <day>01</day>
            <volume>71</volume>
            <issue>14</issue>
            <fpage>1839</fpage>
            <page-range>1839-64</page-range>
            <pub-id pub-id-type="pmid">21942976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reserva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Perlman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vasicek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Coprescription of Isotretinoin and Tetracyclines for Acne is Rare: An Analysis of the National Ambulatory Medical Care Survey.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>45</fpage>
            <page-range>45-48</page-range>
            <pub-id pub-id-type="pmid">32038749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Demir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tercan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aribo&#x0011f;an</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O&#x0011f;uzkurt</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Ergotamine-induced lower extremity arterial vasospasm presenting as acute limb ischemia.</article-title>
            <source>Diagn Interv Radiol</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-7</page-range>
            <pub-id pub-id-type="pmid">19821256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tzontcheva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Denikova</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Analytical interference of drugs on the fluorimetric determination of urinary catecholamines.</article-title>
            <source>Clin Chim Acta</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>297</volume>
            <issue>1-2</issue>
            <fpage>217</fpage>
            <page-range>217-23</page-range>
            <pub-id pub-id-type="pmid">10841923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urban</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nicoletti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Aithal</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Odin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ostrov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cirulli</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>Drug-Induced Liver Injury Network (DILIN)</collab>
              <collab>Pharmacogenetics of Drug-Induced Liver Injury group (DILIGEN)</collab>
              <collab>International Serious Adverse Events Consortium (iSAEC)</collab>
            </person-group>
            <article-title>Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B&#x02217;35:02 as a risk factor.</article-title>
            <source>J Hepatol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>137</fpage>
            <page-range>137-144</page-range>
            <pub-id pub-id-type="pmid">28323125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sokalski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berkelhammer</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Minocycline-induced hepatitis with autoimmune features and neutropenia.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-5</page-range>
            <pub-id pub-id-type="pmid">9706776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raymond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Still leaving stains on teeth-the legacy of minocycline?</article-title>
            <source>Australas Med J</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>139</fpage>
            <page-range>139-42</page-range>
            <pub-id pub-id-type="pmid">26045724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karatzas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paridis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kozyrakis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tzortzis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Samarinas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dailiana</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Karachalios</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fanconi syndrome in the adulthood. The role of early diagnosis and treatment.</article-title>
            <source>J Musculoskelet Neuronal Interact</source>
            <year>2017</year>
            <month>Dec</month>
            <day>01</day>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>303</fpage>
            <page-range>303-306</page-range>
            <pub-id pub-id-type="pmid">29199190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phillips</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Eastwood</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Gower</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>De Wardener</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Tetracycline poisoning in renal failure.</article-title>
            <source>Br Med J</source>
            <year>1974</year>
            <month>Apr</month>
            <day>20</day>
            <volume>2</volume>
            <issue>5911</issue>
            <fpage>149</fpage>
            <page-range>149-51</page-range>
            <pub-id pub-id-type="pmid">4825113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carney</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Butcher</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dawborn</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Pattison</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Minocycline excretion and distribution in relation to renal function in man.</article-title>
            <source>Clin Exp Pharmacol Physiol</source>
            <year>1974</year>
            <season>Jul-Aug</season>
            <volume>1</volume>
            <issue>4</issue>
            <fpage>299</fpage>
            <page-range>299-308</page-range>
            <pub-id pub-id-type="pmid">4459000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agwuh</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>MacGowan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-65</page-range>
            <pub-id pub-id-type="pmid">16816396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LaPlante</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Dhand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lauterio</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance.</article-title>
            <source>Ann Med</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1686</fpage>
            <page-range>1686-1700</page-range>
            <pub-id pub-id-type="pmid">35723082</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dowd</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kippes</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Delate</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy.</article-title>
            <source>Thromb Res</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>130</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-6</page-range>
            <pub-id pub-id-type="pmid">22221937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raebel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Magid</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy.</article-title>
            <source>Pharmacotherapy</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>8</issue>
            <fpage>1055</fpage>
            <page-range>1055-61</page-range>
            <pub-id pub-id-type="pmid">16207095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25180.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mansell</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional collaboration in health care: Lessons to be learned from competitive sports.</article-title>
            <source>Can Pharm J (Ott)</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>148</volume>
            <issue>4</issue>
            <fpage>176</fpage>
            <page-range>176-9</page-range>
            <pub-id pub-id-type="pmid">26448769</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
